An increased number of CD40-high monocytes in patients with Crohn's disease

N Sawada-Hase1, T Kiyohara, J Miyagawa

  • 1Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Japan.

Insights

CD40 expression differs between Crohn's disease (CD) and ulcerative colitis (UC) patients. CD40-high monocytes in CD may contribute to disease pathogenesis, potentially aiding in differentiating CD from UC.

Area of Science:

  • Immunology
  • Gastroenterology

Background:

  • CD40-CD40 ligand (CD40L) interaction is crucial for T-cell immunity.
  • This interaction is implicated in the pathogenesis of inflammatory bowel diseases (IBD).

Purpose of the Study:

  • To investigate CD40 expression in peripheral blood mononuclear cells (PBMNCs) and tissue specimens.
  • To assess CD40-stimulated interleukin (IL)-12 release from PBMNCs in IBD.

Main Methods:

  • Flow cytometry and immunohistochemistry were used to examine CD40 expression.
  • Enzyme-linked immunosorbent assay (ELISA) measured IL-12 release from cultured PBMNCs.

Main Results:

  • Increased CD40 expression on B-lymphocytes in ulcerative colitis (UC) compared to Crohn's disease (CD) and controls.
  • Elevated CD40 expression and IL-12 release from monocytes in active CD patients.
  • CD40-positive, CD68-positive cells (macrophages) found in CD-affected mucosa.

Conclusions:

  • CD40 expression patterns in PBMNCs may help differentiate CD from UC.
  • CD40-high monocytes in CD patients likely play a role in disease pathogenesis.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...